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RESUMO
As amiloidoses se caracterizam por mutações no gene codificante da
transtirretina (TTR) no cromossomo 18. A proteína TTR compõe-se de
uma corrente de polipeptídios de 127 resíduos, que constituem uma
proteína homotetramérica de 56kDa com estrutura secundária de folha ß,
que serve como proteína de deslocamento para a tiroxina (T4), e uma
proteína de ligação ao retinol (vitamina A). O principal local de produção
dessa proteína é o fígado, embora uma pequena quantidade seja
produzida pelo plexo coroide e pelas células retinianas. O gene
codificante da TTR (18q11.2-12) é pequeno (7 kb) e contém quatro
éxons. As mutações convertem-se em perda do equilíbrio do tetrâmero
proteico. Surgem assim, fibrilas amiloides (FA) em cadeias não
ramificadas de 10 a 12 nm de diâmetro e fibrilas indissolúveis, que se
condensam nos tecidos e órgãos. As síndromes concernentes ao
acúmulo da proteína TTR são: polineuropatia amiloidótica familiar (PAF-
TTR), miocardiopatias (MCP) e amiloidose sistêmica senil (ASS).
Estimativa recente relatou a existência de 5.000 a 10.000 casos de PAF-
TTR no mundo. 
Objetivo: O estudo objetiva elaborar uma plataforma de diagnóstico PAF-
TTR on-line para auxiliar como ferramenta de contribuição para o estudo
da epidemiologia e facilitar o diagnóstico.
Métodos: O projeto baseou-se em uma pesquisa bibliográfica capaz de
levantar evidências clínicas e epidemiológicas na elaboração de uma
plataforma facilitadora (pesquisa aplicada). 
Resultados: O resultado alcançado foi a elaboração da plataforma
contendo um questionário, que tornará o trabalho dos profissionais mais
dinâmico, barato e eficiente, caracterizando melhor a doença e
promovendo um diagnóstico precoce. 
Conclusão: A plataforma poderá tornar-se recurso valioso para
caracterização, diagnóstico e futuro estudo epidemiológico da PAF-TTR.
Palavras-chave: Amiloidoses. Mutação. Transtirretina. Polineuropatia.
Epidemiologia
¹Neurologista - Universidade Federal Fluminense (UFF). Niterói/RJ, Brasil; ²Doutora em Neurologia – UFF, Professora Adjunta de Neurologia – UFF, 
 Niterói/RJ, Brasil;  ³Neurologista – UFF, Niterói/RJ, Brasil;   Neurologista – UFF, Niterói/RJ, Brasil;                      
  Doutor em Neurologia - Universidade Federal do Rio de Janeiro (UFRJ), Professor Titular de Neurologia da UFF, Niterói/RJ, Brasil.
Corresponding Author: Arielle Kirmse – drariellekirmse@gmail.com
Universidade Federal Fluminense, Niterói, Rio de Janeiro, Brasil
Conflict of interests: the authors declare no competing interests.
Funding: This research did not receive any specific grant from
funding agencies in the public, commercial, or not-for-profit sectors.
ABSTRACT
Amyloidosis are characterized by mutations in the gene coding
for transthyretin (TTR), located on chromosome 18. TTR is a set
of four 127-aminoacid polypeptides structured as homo-
tetrameric protein of 56 kDa with a secondary ß sheet structure.
It plays the role of thyroxin (T4) carrier, and has a binding
domain for retinol (vitamin A). It is synthesized in the liver,
although a small quantity is also produced by the choroid
plexus, and retinal cells. Mutations of this gene result in loss of
tetramer stability. Insoluble amyloid fibrils (AF) are formed and
deposited in tissues and organs. The abnormal aggregation of
TTR protein trigger several syndromes, such as familial amyloid
polyneuropathy (FAP-TTR), cardiomyopathies (CMP), and
senile systemic amyloidosis (SSA). It is estimated there are
5,000 to 10,000 cases of FAP-TTR globally. 
Objective: The study intends to develop an online platform for
the diagnosis of FAP-TTR. The aim is to facilitate the diagnosis
process and promote a tool for epidemiological study. 
Methods: The project was based on a literature review featuring
clinical and epidemiological evidence for the development of a
practical platform (applied research). 
Results: It was elaborated a platform containing a questionnaire
to allow a more dynamic, cheaper, and efficient operation,
mediated by a better characterization of the disease to enable
its early diagnosis. 
Conclusion: The platform might become a valuable resource
for the characterization, diagnosis, and future epidemiological
study of FAP-TTR.
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   Familial Amyloid Polyneuropathy (FAP) due to
transthyretin (TTR) gene mutation is the most common
presentation among hereditary amyloidosis and is
characterized by high morbidity and mortality rates. It is a
rare and progressive autosomal dominant disease caused
by transthyretin (TTR) instability, leading to fibrillar protein
aggregates and consequent deposits of amyloid fibrils.
Once accumulated in the peripheral nervous system, it
results in sensory-motor polyneuropathy with
dysautonomia¹¹.
            FAP was first reported in the north of Portugal, where
the missense variant was most prevalent. Later, the disease
was observed in large groups of individuals in Japan and
Sweden. It was also reported in Brazil. However,
epidemiological data in this country are still very scarce    .
The diagnosis of FAP-TTR is confirmed by biopsy/genetic
test, which allows the identification/visualization of amyloid
deposits or amyloidogenic mutation, respectively² . The
assumed difficulty to access research centers and the need
for preliminary treatment reinforce the importance of a
facilitating tool for the FAP-TTR diagnosis.
        Therefore, a questionnaire was developed based on
the literature review, considering the disease’s primary
clinical and epidemiological aspects. The objective of the
questionnaire is to aid in screening FAP-TTR patients. The
tool is easy and quick to use. Free access was made





a) If the patient’s signed consent form (ICF-Informed
Consent Form) was not presented by the neurologist;
b) If the acceptance form from the patient was not
presented (patient ICF);
Patients with a suspected diagnosis of FAP-TTR who do not
show written evidence of acceptance (ICF).
             An exclusive virtual environment was developed by
a programmer linked to a private company so that the
Familial Amyloid Neuropathy Platform was made available
to any interested professional at www.neuropatia.com.br.
           Every time a questionnaire is answered, the results
will be sent directly to the Researcher, and will be possible
to be analyzed in real-time. A collaborative and networked
approach to FAP-TTR management, associated with further
epidemiological knowledge, will allow the consistent
sharing and the use of new data to improve the prognosis
and quality of life of the patients and knowledge about the
epidemiology of this disease in Brazil.
           For the following ten questions, different scores were
established, totaling the maximum result of 13 points. The
higher the score, the greater the possibility of a positive
diagnosis for FAP-TTR. The questions were based on the
most relevant symptoms mentioned in the leading
scientific studies, also considering the hereditary character
of the comorbidity. The weight of each question does not
depend on the patient’s particular characteristic since the
objective is to find similarities in the cases based on
standardized data.
METHODOLOGY
           This study used two specific techniques: bibliographic
and applied research. 
      Bibliographic research was used to fundament the
essential knowledge for the comprehension, analysis, and
discussion of the topic in question. To achieve this goal,
academically recognized research instruments such as
PUBMED and Academic Google platforms were used. The
expression familial amyloid polyneuropathy (polineuropatia
amiloidótica familiar) was used as the main descriptor.
        An exploratory applied research, also called Pilot Study,
was necessary at a second moment to achieve the main
specific goal: to create an online platform directed to help
professionals based on a quick, precise, and low-cost
diagnosis of FAP-TTR.
           It is important to emphasize that this study aims only
at creating a tool that may help in the diagnosis of FAP-TTR.
Furthermore, its applicability, sensitivity, and accuracy can
be evaluated along with major research reference centers
such as CEPRAM (Centro de Pesquisas Antonio Rodrigues
de Melo) located in Rio de Janeiro.
           A questionnaire was organized to establish the main
criteria for the identification of the clinical condition in
question. The questionnaire (Attachment 1) contains 11
questions – the first one being only additional information
(if the patient has a diagnosis of diabetes mellitus type 2 —
DM2, and if they are on a glycemic control).
Inclusion criteria
For neurologists who will use the platform in the future:
For participating patients:
a) Active neurologists;
b) Neurologists with patients suspected of FAP-TTR
diagnosis;
a) Patients with suspected diagnosis of FAP: small-fiber
neuropathy, symmetric and progressive axonal sensory-
motor polyneuropathy, autonomic symptoms, positive
family history, bilateral carpal tunnel syndrome which may
be associated with non-ischemic cardiomyopathy,
ophthalmopathy, and kidney injury of undetermined cause.
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        This study is in line with resolution number 196/96
and the 1988 Medical Code of Ethics. Since the research is
based purely on developing a virtual diagnostic aid
platform for FAP-TTR, there is no need for contact or
evaluation of the patients by the physicians of the research
team. This project was approved by the Antonio Pedro
Hospital’s Institutional Review Board under number
07284818.0.0000.5243.
The result of this study was the creation of a free, online
tool of easy access that physicians can use whenever they
suspect the diagnosis of FAP-TTR for a patient.
     The platform will provide a structure capable of
synthesizing symptoms and generating data that will
promote low-cost diagnosis. This resource will also allow
the identification of groups that are more likely to present
familial amyloid polyneuropathy, and the endemic areas.
Hopefully, it will contribute to timely treatment, thereby
reducing expenses for patients, government or health
insurance.
      Plans of a future partnership with the Brazilian
reference center CEPRAM and other institutions for
applying this platform will allow statistically quantifying its
sensitivity and accuracy.
            The data collected may be insufficient to predict the
risks of developing the disease. However, in the future, the
platform will aid the physicians to quantify the minimum
chance of the patient being a carrier. This will work as a
screening tool to highlight patients at higher risk of
developing the disease and who need closer monitoring.
The platform as a screening and surveillance tool will also
foster the generation of objective features to estimate the
probability of disease development.
RESULTS
DISCUSSION
Familial amyloid polyneuropathy (FAP) is a hereditary, rare,
progressive condition with high morbidity and mortality. It
originates from the instability of the transthyretin protein,
generating fibrilar protein aggregates, culminating in a
widespread accumulation of amyloid.
             Amyloidoses are classified according to the type of
amyloid protein that causes the disease: TTR,
apolipoprotein A1 (APLA1), or gelsolin (GL)  .
            The PNS and the heart are frequently affected, and
most patients show sensory-motor polyneuropathy and
dysautonomia. It can also affect leptomeninges and eyes
and, less frequently, the kidneys.
           Amyloidosis is relatively rare and can be systemic or
punctual, spontaneous or hereditary.
     TTR is the most common form of hereditary
amyloidosis. Pathogenic substitution frequently occurs by
the substitution of valine for methionine in position 50 of
the gene TTR (Val50Met), nevertheless, other pathogenic
substitutions have already been described. Currently, 119
punctual mutations have been identified, including 113
pathogenic variants in TTR gene 20 .
            TTR is a plasmatic tetrameric transport protein;
each monomer consists of a single polypeptide chain of
127 amino acid residues of about 14,000Da. The entire
structure is approximately 56,000Da. The tetrameric
structure has surface receptors for retinol-binding proteins
(vitamin A), and binding sites for thyroxine (T4). The
protein breakdown leads to inadequate aggregation and
deposition of amyloid in various systems and organs. Most
of the plasma TTR protein is synthesized by the liver, but
some are produced in the pigment epithelium of the retina
and in the choroid plexus of the brain.
               Recently studies have reported TTR synthesis in
Schwann cells of the peripheral nervous system (PNS). In
humans, the TTR gene has been found in chromosome 18
in locus 18p11.1-q12.3. Its size is approximately 7kb, and it
has four exons² . Most mutations are the product of a
single substitution of nucleotides in the TTR gene. The
abnormal amyloid fibrils (AF) were found to result from a
replacement of valine by methionine at position 50 of the
TTR gene (Val50Met). Since then, several other missense
variants in the TTR gene have been described, but
Val50Met remains the most common mutation.
                FAP-TTR was first described by Andrade (1952)¹  in
northern Portugal and was later observed in Japan and
Sweden. Initially, its occurrence was believed to be
restricted to endemic areas, but with the advanced
techniques developed by immunohistochemistry and
molecular biology, the diagnosis became less
underestimated and could be observed even in sparsely
isolated cases² . In the Brazilian population, the most
common mutation is the TTRVal50Met, which is due to the
Portuguese colonization   . To date, four other missense
variants       have        been           reported:    TTRVal71Ala   , 
TTRlle107Val³, TTRAla19Asp   , and TTRAsp38Tyr   . The age
at onset of symptoms varies from the second to the ninth
decade of life.
                Sensory-motor polyneuropathy occurs in patients
with familial amyloid polyneuropathy due to mutation of
the transthyretin gene (FAP-TTR) associated with
autonomic disorders and non-neurological manifestations.
Patients may have different patterns of neuropathy such
as focal neuropathies, sensory-motor polyneuropathy,
autonomic neuropathy, or any combination of all these
types. The most common is length-dependent
polyneuropathy. However, the disease may manifest as
focal deficits resulting from local amyloid deposits. The
medium nerve of the wrist is a place affected by FAP. Some
patients present an early deterioration due to autonomic
disfunction   .
       The initial symptoms are burning of the feet,
numbness, and loss of thermal sensibility. Symptoms
begin in the lower limbs and may extend to the upper
limbs.
             Motor alterations are related to loss of strength
and muscular atrophy in the feet and legs, occurring after
sensitive symptoms and usually associated with
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             Cardiovascular, genitourinary and gastrointestinal symptoms
are also frequent and there may be orthostatic hypotension,
dizziness, fatigue, and blurred vision. Gastrointestinal symptoms
include postprandial diarrhea alternating with constipation    .
         The diagnosis of FAP-TTR should be considered in the
presence of progressive sensory-motor polyneuropathy associated
with at least one of the following: family history of small-fiber
neuropathy, autonomic dysfunction, cardiac involvement, diarrhea
or constipation, weight loss, bilateral carpal tunnel syndrome, renal
involvement, or vitreous opacities¹¹ .
            The accepted tools for the definitive diagnosis are tissue
biopsy and genetic tests. However, the diagnosis should be guided
by clinical findings, followed by investigation with additional tests
such as electroneuromyography (ENMG), electrocardiogram (ECG),
Holter, and two-dimensional echocardiographic scan should be
performed during the follow-up to screen for cardiac involvement.
                  Genetic tests detect specific amyloidogenic TTR mutations.
When patients have suspected FAP, some differential diagnoses
should be considered: light chain amyloidosis, chronic
inflammatory demyelinating polyneuropathy, and other
neuropathies (Fabry disease, leprosy neuropathy, among others).
The diagnosis by tissue biopsy/genetic test is based on the
identification/visualization of amyloid deposits or amyloidogenic
mutation² . The FAP mutant gene is detected by DNA sequence
analysis in exons 2, 3, and 4 of the TTR gene. It can determine
whether the sequences found show mutations compared to the
original template deposited in the NCBI (National Center for
Biotechnology Information) – Reference Sequence: NG_009490.1.
This analysis is performed by PCR (polymerase chain reaction),
using the donated biological material as the substrate to confront
the template¹² . Genetic testing and tissue biopsy of affected organs
are performed in few places in Brazil and are usually expensive,
often forcing patients to travel long distances to obtain a definitive
diagnosis¹³ . There are specific drugs for FAP-TTR that minimize or
block  amyloid deposits, aiming to better offer quality of life and
reduce morbidity and mortality. Gene therapy comes up as
promising       .
     Previously, the only treatment was orthotopic liver
transplantation (OLT). However, candidates for this therapy were
patients with an early diagnosis (before age 50), confirmation of the
TTRVal50Met mutation, minimum duration of the disease and
greater modified body mass index (mBMI). Innovative procedures
have gained prominence in recent years, such as tetramer
stabilizers and gene therapies     .
               The classification of the FAP-TTR stages is based on different
scores 2 .
1. Clinical staging of FAP-TTR:
Stage 0: Asymptomatic;
Stage 1: Light; able to walk; symptoms limited to lower limbs;
Stage 2: Moderate; able to walk but needs assistance;
Stage 3: Serious; confined to a wheelchair or bed with diffuse 
weakness
2. Polyneuropathy Disability score (PND score):
I: Sensory alterations in the extremities, but able to walk
(stage 1)
II: Difficulty walking, but still does not need assistance
(stage 1)
IIIa: Walks with unilateral support (stage 2)
IIIb: Walks with bilateral support (stage 2)
IV: Confined to a wheelchair or bed (stage 3).
           Considering the mentioned data and the importance
of a tool that may help in the diagnosis of patients
presenting FAP-TTR, the project focused on elaborating a
questionnaire which takes into account the main clinical
and epidemiological aspects of the illness as well as its
hereditary and an easy access to the virtual environment. 
       The selection of the questions was based on a
previous bibliographic review done before the elaboration
of the questionnaire. It was based on the most relevant
signs and symptoms of the disease —mentioned in the
leading scientific studies— besides valuing the hereditary
characteristic of the comorbidity.
             The initial question is just an additional information
and does not interfere with the final score of the
questionnaire. It questions whether the patient presents a
diagnosis of diabetes mellitus type 2 (DM2), and if there is
glycemic control since this disease promotes a small-fiber
neuropathy which also figures as a characteristic for FAP
diagnosis, therefore being of great importance the
previous knowledge whether or not the patient has DM2 in
order to exclude factors that might bias in the final result.
Question 01. “Is FAP family history confirmed? —First- or
second-degree kinship”— was rated 2. It was considered
relevant due to the hereditary characteristic of FAP already
identified by Corino de Andrade in 1952, and later having
its autosomal dominant inheritance genetically elucidated.
Question 02. “Neuropathic pain? Ex: burning pain,
stabbing or shock” —was also rated 2. Initial
manifestations are related to sensitive symptoms (small-
fiber neuropathy), which mainly affect lower members
with numbness or neuropathic pain (burning). Initially, the
types of sensitivity committed are pain and temperature,
highlighting the importance of valuing such an nonspecific
symptom regarding such a crippling disease. Initially, it
appears to be a small-fiber neuropathy    .
Question 03. “Dysautonomia? —Orthostatic hypotension,
thermal alterations at extremities—hyperemia/cyanosis,
constipation/diarrhea, erectile dysfunction” —was also
rated 2.0 as, according to the analyzed literature, a
significant amount of patients present dysautonomia. The
characterization of these symptoms is described in
between brackets in the question, highlighting the fact that
the presence of dysautonomia as an initial symptom of the
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and more severe progression of the disease, thus justifying
the importance of a high score for this question.
“Autonomic neuropathy is followed by the installation of
sensitive neuropathy and less frequently can present itself
as the initial symptom of the disease".
The following questions were valued at 1.0 point each,
being considered less significant for the diagnosis although
necessary for a deeper view of the disease. When question
04 was elaborated—“Nonischemic cardiopathy? Do not
include patients with hypokinesia, segmental akinesia”—it
was considering cardiac amyloid deposit, which is observed
in patients with ATTR.
Question 05. “Bilateral carpal tunnel syndrome?” — Was a
must since it refers to a frequently described symptom of
FAP-TTR patients due to the component of amyloid deposit
on the median nerve, which generates a bilateral
compressive syndrome. The amyloid deposits can
accumulate in specific areas generating focal lesions such
as bilateral carpal tunnel syndrome—more severe and less
responsive to decompression surgery than idiopathic
forms, described as an early symptom of ATTR   .
Question 06. “Progressive symmetric sensorimotor
polyneuropathy?”—The objective is to identify the main
routine and clinical aspect of the disease, a neuropathy that
initially affects the lower limbs with sensitive symptoms,
evolving to motor findings and later affecting the upper
limbs. It is an axonal length-dependent sensory-motor
neuropathy associated with autonomic symptoms with
initial impairment of small fibers.
Question 08. “Probable ophthalmopathy?—Abnormal
vessels in the conjunctiva, alteration of the shape of the iris, 
amyloid deposition in the
retina/vitreous/crystalline/conjunctiva, not including 
 isolated ischemic or hypertensive retinopathy, or
glaucoma”—seemed relevant since not too rarely amyloid
deposit occurs in the vitreous body justifying the
ophthalmological symptoms in the general context of such
entity.
Question 09. “Doubtful family history? Family of
Portuguese origin, first degree relative with a history of
severe restrictive heart failure at a young age/affected with
an inability to walk by severe sensory-motor
polyneuropathy”—is justified in the same way as Question
01; however, in this case, the family diagnosis is suspected,
not established.
Question 10. “Weight loss of undetermined cause?”—the
choice of this question is imperative since weight loss of
undetermined cause is highly related to this disease.
Dysautonomia contributes to the alternation between
diarrhea and constipation, leading patients to a significant 
weight loss. Besides the dysautonomic symptoms,
throughout the disease’s progression, the patient presents
sustained weight loss that is not justified solely by their
gastrointestinal symptoms   .
             The questionnaire was prepared in a structured
way to elucidate the ethnic aspects of the patient, hence
trying to identify his/her origin and the clinical aspects of
the disease.
               Regarding the evaluation criteria, the score chosen
for each question does not rely on the patient’s particular
characteristics, since the aim is finding whatever there is in
common in the analysis, allowing thus to build a platform
that will present the data in a standardized manner.
         The FAP-TTR diagnosis platform can be accessed
easily through a link available online containing assertive
questions about the condition, scoring the answers in
different scales, and generating a data bank for future
characterization of the clinical/epidemiological aspects of
the disease.
             The description of the processes used is relevant.
Although there are no other similar instruments for
comparison, it reveals knowledgeable strategies based on
scientific evidence on the methodological easiness and
challenges found in different events and studies. It is often
impossible to obtain a satisfactory result through
traditional data collection approaches, such as by
presential interviews, by telephone or by written
questionnaires. These methods do not generate results
quickly and efficiently, and also may be expensive In
addition, there is the magnitude of the technological
resources available nowadays and the fact that the
participation rates in epidemiological studies drop when
they are not implemented through modern means and
methods²¹.
                 With the expansion of internet access throughout
the world, studies using virtual environment have shown a
fruitful trend in data collection, being the preferred
method by most research participants²². Even though the
use of the internet in research groups is done mainly by
young people, the use of this tool has grown lately.
Furthermore, it is a resource that allows those involved in
the study to establish agile and rigorous contact with the
predictions, answers, data, probabilities, and other
theories raised.
                In Europe, about 85% of homes have access to
the internet. In Brazil, the proportion reached 120.7 million
people in 2017. According to the study, in 2008, users were
no more than 34%, and in 2017 they were already 74.9%.
Considering these data, virtual questionnaires are an
alternative method for obtaining answers in scientific
research. The use of a virtual tool also disseminates the
necessary information, enabling the development of
research in the area of epidemiology of FAP-TTR. Thus, the
objective of this study was to develop the FAP-TTR
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disseminate it in a virtual environment, to systematize data
collection related to the disease.
CONCLUSION
              Knowledge about Portuguese heritage, the difficulty
of access to large diagnostic centers, the high cost of the
confirmatory tests, and the high morbidity and mortality
rates of this condition support that this tool can contribute
to an early diagnosis and an adequate and timely
treatment. Moreover, it is worth highlighting the advent of
new therapeutic approaches based on genetic
replacement. Therefore, all hypotheses of the need for the
applicability of this tool in the near future are justified.
            Concluding, this platform will serve as an analysis
tool that considers the disease itself and the diseased
patient. Due to its low cost and great benefit, it can be used
constantly in the daily routine of specialists. Hopefully, the
platform will contribute to the improvement and agility of
the diagnosis definition, facilitating both early treatment
onset and the budget estimation for the patient, the
government/the health insurance. In addition, the platform
might enable the monitoring of the therapeutic response
after the diagnosis determination.
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STRUCTURED QUESTIONNAIRE
Title of the project: Familial Amyloid Polyneuropathy: A Proposal for
Epidemiological Study Through the Creation of a Virtual Platform
Researcher: Osvaldo José M. do Nascimento
IDENTIFICATION:
Referred by Dr.: __________________________________________________
Physician's phone: (___)___________________________
Patient's name: _________________________________________________
Gender: (__) F (__) M
Patient’s phone: (___)__________________________
Date of birth: ___/___/___
Address: _____________________________________________
ADDITIONAL INFORMATION:
1) Diagnosed for Type 2 Diabetes mellitus? If YES, Classify by:
WELL CONTROLLED: fasting blood glucose <140 mg/dL and/or Hb <7;
 PARTIALLY CONTROLLED: fasting blood glucose between 140-
200mg/dL and/or Hb between 7-8;
 UNCONTROLLED: fasting blood glucose >200mg/dL and/or Hb>8;
 NOT POSSIBLE TO CLASSIFY
Attachment 1
(dd/mm/yyy or mm/dd/yyy)
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